Ark Therapeutics raises £35.4 million with share placement
Ark Therapeutics Group Plc, which is developing gene-based medicines, has raised a net £35.4 million with an “oversubscribed” placement of its London-listed shares.
News
GSK to develop and commercialise a type-1 diabetes drug
GlaxoSmithKline (GSK) has reached an agreement with Tolerx Inc to develop and commercialise a candidate biologic for the treatment of type-1 diabetes and other autoimmune diseases.
Paediatric waivers recommended for three medicines
The recently formed Paediatric Committee of the European Medicines Agency (EMEA) has issued its first opinions on requests from companies for waivers on the testing of their drug candidates in children.
Imperial Innovations flourishes as a venture capitalist
Imperial Innovations Group Plc, which started operations as a university technology transfer office in 1986, has transformed itself into a venture capital company with about half of its investments in life science companies.
Modern Biosciences to develop University of Aberdeen’s RA compounds
Modern Biosciences Plc has signed an exclusive worldwide licensing agreement with the University of Aberdeen to develop a series of small molecule compounds for the treatment of rheumatoid arthritis (RA).
Pharming Group raises €70 million with convertible notes
Pharming Group NV, a Dutch biotech company with an orphan drug candidate for treating hereditary angioedema, said it has raised €70 million through a placement of five-year convertible notes bearing 6.875% annually.
UK method of pricing drugs is to remain voluntary despite changes
The UK government is planning to change the Pharmaceutical Price Regulation Scheme (PPRS) but whatever happens it will remain a voluntary agreement, Richard Barker, director general of the Association of the British Pharmaceutical Industry (ABPI) told journalists.
EMEA recommends seven drugs for approval
The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that seven products be approved for sale in Europe, including two biosimilar medicinal products and one generic.
TopoTarget A/S launches first product in the US
TopoTarget A/S of Denmark, whose founders and managers are clinical cancer specialists, has launched its first product on the US market. The product, Totect, is a treatment for patients who experience a specific type of accident during chemotherapy.
The London Agreement on patents gets the go ahead in France
The French Senate has approved the London Agreement, which reduces the translation requirements for patents in Europe.